Blocking extracellular Galectin-3 in patients with osteoarthritis
Objective: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). Methods: 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules)...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Contemporary Clinical Trials Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865419302637 |
| _version_ | 1819163353771147264 |
|---|---|
| author | Alec R. Andrews Ana D. Fernandes Seth E. Brownmiller Yousif Hanna Mark C. Fisher Christene A. Huang |
| author_facet | Alec R. Andrews Ana D. Fernandes Seth E. Brownmiller Yousif Hanna Mark C. Fisher Christene A. Huang |
| author_sort | Alec R. Andrews |
| collection | DOAJ |
| description | Objective: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). Methods: 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. Results: Patients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. Conclusion: Treatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo. Keywords: Osteoarthritis, Galectin-3, Modified citrus pectin |
| first_indexed | 2024-12-22T17:42:47Z |
| format | Article |
| id | doaj.art-cf8dc3a1d87c4944804f39068a1e2054 |
| institution | Directory Open Access Journal |
| issn | 2451-8654 |
| language | English |
| last_indexed | 2024-12-22T17:42:47Z |
| publishDate | 2020-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Contemporary Clinical Trials Communications |
| spelling | doaj.art-cf8dc3a1d87c4944804f39068a1e20542022-12-21T18:18:23ZengElsevierContemporary Clinical Trials Communications2451-86542020-03-0117Blocking extracellular Galectin-3 in patients with osteoarthritisAlec R. Andrews0Ana D. Fernandes1Seth E. Brownmiller2Yousif Hanna3Mark C. Fisher4Christene A. Huang5Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USADepartment of Rheumatology, Massachusetts General Hospital, Boston, MA, USADepartment of Rheumatology, Massachusetts General Hospital, Boston, MA, USADepartment of Rheumatology, Massachusetts General Hospital, Boston, MA, USADepartment of Rheumatology, Massachusetts General Hospital, Boston, MA, USACenter for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA; Department of Surgery, Division of Plastic and Reconstructive Surgery, Division of Transplant Surgery, University of Colorado School of Medicine, Aurora, CO, USA; Corresponding author. 12700 E 19th Ave RC2-6100, Aurora, CO, 80045, USA.Objective: This pilot clinical trial examined the efficacy of blocking extracellular Galectin-3 (Gal-3) with modified citrus pectin (MCP), in patients suffering from knee osteoarthritis (OA). Methods: 50 patients were randomized in a 1:1 ratio to receive MCP or placebo at a dose of 4 g (5 capsules) twice daily for 12 weeks. Serum Gal-3 levels and OA severity were evaluated at baseline and 12 weeks. Gal-3 levels were detected by sandwich ELISA and OA severity was determined using WOMAC-knee, SF-36, and RAPID3 surveys during these visits. MCP tolerability was assessed by a basic metabolic panel during a week 6 follow up visit. Results: Patients enrolled in both the MCP treatment and placebo groups shared similar baseline characteristics in OA severity, serum Gal-3 levels, and pain management. Improvement across all surveys was noted independent of supplement or placebo treatment. No significant change in Gal-3 levels were observed in either cohort over the 12-week study. Conclusion: Treatment of knee OA with a 12-week course of MCP did not significantly improve disease burden compared to placebo. Keywords: Osteoarthritis, Galectin-3, Modified citrus pectinhttp://www.sciencedirect.com/science/article/pii/S2451865419302637 |
| spellingShingle | Alec R. Andrews Ana D. Fernandes Seth E. Brownmiller Yousif Hanna Mark C. Fisher Christene A. Huang Blocking extracellular Galectin-3 in patients with osteoarthritis Contemporary Clinical Trials Communications |
| title | Blocking extracellular Galectin-3 in patients with osteoarthritis |
| title_full | Blocking extracellular Galectin-3 in patients with osteoarthritis |
| title_fullStr | Blocking extracellular Galectin-3 in patients with osteoarthritis |
| title_full_unstemmed | Blocking extracellular Galectin-3 in patients with osteoarthritis |
| title_short | Blocking extracellular Galectin-3 in patients with osteoarthritis |
| title_sort | blocking extracellular galectin 3 in patients with osteoarthritis |
| url | http://www.sciencedirect.com/science/article/pii/S2451865419302637 |
| work_keys_str_mv | AT alecrandrews blockingextracellulargalectin3inpatientswithosteoarthritis AT anadfernandes blockingextracellulargalectin3inpatientswithosteoarthritis AT sethebrownmiller blockingextracellulargalectin3inpatientswithosteoarthritis AT yousifhanna blockingextracellulargalectin3inpatientswithosteoarthritis AT markcfisher blockingextracellulargalectin3inpatientswithosteoarthritis AT christeneahuang blockingextracellulargalectin3inpatientswithosteoarthritis |